
News|Videos|November 6, 2023
PSMAfore: Lutetium-177–PSMA-617 in Metastatic CRPC
Shared insight from Rana McKay, MD, and the Oncology Brothers on updated data from PSMAfore and the use of Lutetium-177–PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
2
Phase 3 ENHANCE Trial: Magrolimab Adds Toxicity, Not Benefit, in MDS
3
First Patients Dosed With TLX597-Tx in Trial for mHSPC
4
Advanced Renal Cell Carcinoma: Summarizing a Practical First-Line Treatment Algorithm
5
































